Dragonfly Therapeutics, Inc., a US-based biotechnology company developing novel therapies that harness the immune system to treat a broad range of diseases, announced on Tuesday that it has dosed its first patient in the phase two study of its HER2 targeting TriNKET DF1001.

The trial is recruiting patients across a range of advanced solid tumour indications at 34 sites in the United States and Europe.

The product is the first TriNKET to enter into Phase two trials. During the dose escalation in the phase one study, DF1001 was reportedly well-tolerated with no dose limiting toxicities. The company said that the study indicated encouraging pharmacodynamic impacts, including infiltration infiltration of NK cells and T cells into tumours. It also showcased clinical response as a monotherapy and in combination with nivolumab or nab-paclitaxel, with tumour burden decrease across various solid cancer types indicating both HER2-low and HER2-high, and heavily pre-treated patients.

The DF1001 phase two trial is intended to expand development of DF1001 both as monotherapy and in combination with multiple agents, including Opdivo and Abraxane.